UK NICE recommends use of Lartruvo (olaratumab) for adults with advanced soft tissue sarcoma- Eli Lilly

The National Institute for Health and Care Excellence (NICE) has published its Final Appraisal Determination on Lartruvo (olaratumab), from Eli Lilly, and in combination with current standard treatmeant doxorubicin the drug is now recommended for use as an option for some adults with advanced soft tissue sarcoma. To be eligible, patients must have not had any previous systemic chemotherapy for the condition, and cannot have curative treatment with surgery or their disease does not respond to radiotherapy.

Lartruvo has been recommended through the managed access system because NICE judged there to be uncertainties about its long-term effectiveness. Olaratumab plus doxorubicin can increase overall survival, while at the same time having a generally manageable tolerability profile. The guidance will be updated in December 2020, by which time the ANNOUNCE trial results will be ready.